One Zyme turns the world's scientific, clinical, regulatory, patent, financing, and conference signals, including deep China coverage, into an evidence layer built for healthcare-focused hedge funds, asset managers, and venture investors.
Diligence used to mean a Cortellis pull in one tab, GlobalData in another, PitchBook, Evaluate, and Citeline in three more, reconciled by hand. One Zyme reads the same underlying corpus and resolves it into a single, cited, structured intelligence layer.
One Zyme flags a company or asset the moment the evidence turns, a regulatory step, a trial initiation, a financing, a patent family, often months before it reaches consensus coverage. The gap between our flag and the public moment is your window.
ASCO, AACR, ASH, ESMO, ESC, ADA and more, One Zyme reads each abstract, poster, and late-breaker and turns it into structured data you can filter by drug, target, indication, phase, conference, or date, so a readout becomes a position input instead of a scramble.
Pharma and biotech conference presentations, structured for search.
One Zyme plots every approach by competitive density and unmet need at once. The differentiated position isn't just the empty space, it's the open space where the science is thin, the need is high, and the story hasn't been told yet.
China now originates a large share of the world's leading-edge biopharma innovation, and it's where Western research tools go dark. One Zyme brings China directly into your diligence: surfacing assets, competitors, financings, and structure traditional databases miss.
Spot programs before they reach Western awareness.
Track IND filings and active China trials in real time.
Catch priority review and breakthrough designations.
See raises, licensing, and M&A as they form.
Resolve subsidiaries, JVs, and related parties.
Map CNIPA families and cross-border filings.
Track catalysts, readouts, and inflection points across the coverage universe, with cited evidence behind every thesis and China visibility built in.
Source emerging assets and companies pre-consensus, benchmark them against the field, and diligence the science, IP, and competitive set in one place.
Monitor whole therapeutic areas continuously, understand where innovation is forming, and build conviction on evidence rather than headlines.
Every investor workflow runs on the same agents, data, and evidence trail that power the rest of the platform.
Explore Models & Data →Get a strategic briefing tailored to your fund's therapeutic focus, coverage universe, and diligence workflow.
